Williamsville, NY United States
22nd Century Group, Inc., a plant biotechnology company, provides technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding. It offers premium cigarettes under the RED SUN and MAGIC brands; and SPECTRUM, a line of research cigarettes for use in independent clinical studies. The company's products under development include BRAND A, a very low nicotine cigarette; X-22, a tobacco-based botanical medical product for use as an aid to smoking cessation; and BRAND B, a low-tar-to-nicotine ratio cigarette. In addition, it engages in contract manufacturing business for third-party branded tobacco products. The company has scientific collaborations with the University of Virginia and Anandia Laboratories, Inc. to develop proprietary hemp strains with less than 0.3% dry weight content of delta-9-tetrahydrocannabinol. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Williamsville, New York.
[stock_market_widget type="chart" symbol="XXII" chart="line" range="1y" interval="1mo" line-color="rgb(49, 125, 189)"]
Full Service Domestic Banking –
We offer scalable banking solutions in the U.S.,providing you with access to the bank services you need.
Payment Processing –
We provide U.S. based payment processing for accepting ATM Debit cards with the name of your business. In addition, we can provide online acceptance of Debit & Credit Cards for your CBD web based business.
We have lending partners who work specifically with the cannabis industry so we can get you the funding you need!
Seed-to-Sale Inventory and Cash Management –
We offer Seed-To-Sale and Cash Management Systems that track inventory and handle cash transactions safely and securely at your business.
Security Services –
We partner with Security Services for asset protection and safety. Why risk the safety of you or your employees when you don’t have to.
Napanee, ON Canada
ABcann Global Corporation manufactures and distributes medical cannabis. The company is headquartered in Napanee, Canada.
[stock_market_widget type="chart" symbol="ABCCF" chart="line" range="1y" interval="1mo" line-color="rgb(49, 125, 189)"]
Suite 8, Level 2 57 Shenton Avenue
Joondalup, WA Australia
AusCann Group Holdings Ltd researches, develops, cultivates, produces, and sells clinically validated cannabis medicines to patients in Australia. The company has a strategic partnership with Tasmanian Alkaloids Pty Ltd. AusCann Group Holdings Ltd is based in Joondalup, Australia.
[stock_market_widget type="chart" symbol="ACNNF" chart="line" range="1y" interval="1mo" line-color="rgb(49, 125, 189)"]
Toronto, ON Canada
Cannabis Wheaton Income Corp. operates as a cannabis streaming company. It provides funding for cannabis facility expansions, operations, and initial construction in exchange for minority equity interests and a portion of the cultivation production. The company was formerly known as Knightswood Financial Corp. and changed its name to Cannabis Wheaton Income Corp. in May 2017. Cannabis Wheaton Income Corp. was incorporated in 1987 and is based in Toronto, Canada.
[stock_market_widget type="chart" symbol="CBWTF" chart="line" range="1y" interval="1mo" line-color="rgb(49, 125, 189)"]
Fort Lauderdale, FL
Established in 2010, BioTrackTHC aims to bring cannabis out of prohibition through transparency, accountability, and scalable growth. As pioneers of seed-to-sale tracking for both business management and government oversight software, the BioTrackTHC team has the professional experience necessary to navigate regulations and enforce compliance across any regulated landscape.
BioTrackTHC’s comprehensive product suite increases transparency and accountability by monitoring key data points during cultivation, harvest, extraction, packaging, transport, and dispensing. In 2013 BioTrackTHC successfully implemented the Washington State Traceability System, the world’s first real time cannabis seed-to-sale traceability program.
Since then, BioTrackTHC has won additional state contracts in Delaware, New Mexico, Illinois, New York and Hawaii, and has been selected as the winner apparent for the government contract in Puerto Rico. In addition, the company has over 2,000 locations using their commercial software and has processed over $10 billion in sales. Headquartered in sunny Ft. Lauderdale, FL, BioTrackTHC also operates satellite offices in Denver, CO, Olympia, WA, Honolulu, HI, and San Juan, Puerto Rico, increasing their national presence and providing them with the industry insights needed to continue upgrading their software as the cannabis industry evolves.
In 2018, BioTrackTHC officially merged with publicly-traded, Helix TCS, Inc. and is traded on the OTCQB: HLIX. Helix TCS provides Technology, Compliance, and Security solutions to the regulated cannabis industry.
Want to learn more about the various software and services BioTrackTHC offers? Learn about all of our cannabis software solutions here.
The CanEx Jamaica Business Conference and Expo is an annual business-to-business (B2B) event that brings together top cannabis industry experts from the U.S., Canada, South and Central America, Europe, Australia and the Caribbean.
Held for the first time in 2016, CanEx Jamaica is responsible for helping numerous businesses create new strategic partnerships. Through world-class speakers and panelists, CanEx Jamaica provides insight into the global direction of the industry and features a mix of high-level discourse and practical opportunity led by global experts with real-life application in the industry.
CanEx Jamaica’s mission is to help establish Jamaica’s place on the international stage while giving entrepreneurs and investors around the world a place to nurture business opportunities. While relationships and strategic partnerships made at CanEx have played an integral role in developing and advancing the local discussion regarding cannabis, the conference now offers a platform for a global conversation, located in the Caribbean.
Vicente Fox, 2018 keynote speaker and former president of Mexico, said: “The cannabis industry offers tremendous economic, health and social benefits in Mexico as in other markets around the world. I welcome the opportunity to share, network and advocate for its continued progress at CanEx Jamaica. The island and this conference offer a powerful platform to push the medical and legal cannabis movement and that is something I fully support.”
Montel Williams, keynote speaker at the 2017 and 2018 CanEx Jamaica conferences, said: “I am excited to participate in CanEx Jamaica because it’s a unique opportunity to gather so many leaders from the international cannabis industry in a place that is so important to cannabis’ history.”
Discussing opportunities for investment, medical advances and uses, as well as the business, legal and regulatory landscape, the conference features keynote addresses, panel discussions, presentations and exhibitions by:
- Investors, Financiers and Business Executives
- Industry Advocates, Policy Makers and Legal Experts
- Farmers, Cultivators and Processors
- Researchers, Physicians and Other Medical Practitioners
While CanEx Jamaica has played a pivotal role in elevating the discussion from a business and industry perspective in Jamaica, the conference continues to expand to provide a platform for an increasingly global conversation. Jamaica has played an important role in the history of cannabis – a role that will evolve as changing regulations are expected to bring substantial benefits to both local and international cannabis companies.
Suite 610 33 Preston Street
Ottawa, ON Canada
CannaRoyalty Corp.is a private equity firm specializing in acquisitions. The firm invests in the legal cannabis sector with a focus on research and intellectual property, consumer brands, and industry infrastructure. It seeks to invest in the United States and Canada. CannaRoyalty Corp. is headquartered in Ottawa, Canada.
[stock_market_widget type="chart" symbol="CNNRF" chart="line" range="1y" interval="1mo" line-color="rgb(49, 125, 189)"]
Unit 1 3280 Langstaff Road
Vaughan, ON Canada
CannTrust Holdings Inc. produces and distributes pharmaceutical grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to the client based on the medication document provided by health care practitioner. The company was incorporated in 2015 and is headquartered in Vaughan, Canada.
[stock_market_widget type="chart" symbol="CNTTF" chart="line" range="1y" interval="1mo" line-color="rgb(49, 125, 189)"]
9th Floor 107 Elm Street
Stamford, CT United States
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with chronic kidney disease associated pruritus undergoing hemodialysis, as well as in Phase II/III clinical trial for the treatment of dialysis patients suffering from uremic pruritus. The company is also developing Oral KORSUVA (CR845/difelikefalin) that has completed Phase I clinical trial to treat uremic pruritus; and in Phase I clinical trial to treat pruritus chronic kidney disease, as well as in Phase I clinical trial for treating pruritus chronic liver disease. In addition, it is developing CR845/difelikefalin Injection, which is in Phase III clinical trial for the treatment of acute post-operative pain; and Oral CR845/difelikefalin that has completed Phase IIb for treating chronic pain, as well as CR701, which is in preclinical trial for the treatment of chronic pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.
[stock_market_widget type="chart" symbol="CARA" chart="line" range="1y" interval="1mo" line-color="rgb(49, 125, 189)"]